PortfoliosLab logo
LNTH vs. APLS
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between LNTH and APLS is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

LNTH vs. APLS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lantheus Holdings, Inc. (LNTH) and Apellis Pharmaceuticals, Inc. (APLS). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

LNTH:

-0.10

APLS:

-1.05

Sortino Ratio

LNTH:

0.28

APLS:

-1.75

Omega Ratio

LNTH:

1.04

APLS:

0.79

Calmar Ratio

LNTH:

-0.21

APLS:

-0.72

Martin Ratio

LNTH:

-0.40

APLS:

-1.74

Ulcer Index

LNTH:

21.03%

APLS:

33.98%

Daily Std Dev

LNTH:

65.39%

APLS:

54.30%

Max Drawdown

LNTH:

-78.62%

APLS:

-82.47%

Current Drawdown

LNTH:

-40.25%

APLS:

-81.31%

Fundamentals

Market Cap

LNTH:

$5.17B

APLS:

$2.19B

EPS

LNTH:

$3.51

APLS:

-$1.80

PS Ratio

LNTH:

3.37

APLS:

2.83

PB Ratio

LNTH:

4.44

APLS:

13.61

Total Revenue (TTM)

LNTH:

$1.54B

APLS:

$775.84M

Gross Profit (TTM)

LNTH:

$984.15M

APLS:

$643.52M

EBITDA (TTM)

LNTH:

$438.66M

APLS:

-$176.07M

Returns By Period

In the year-to-date period, LNTH achieves a -17.44% return, which is significantly higher than APLS's -45.35% return.


LNTH

YTD

-17.44%

1M

-27.02%

6M

-18.40%

1Y

-6.51%

3Y*

5.02%

5Y*

42.21%

10Y*

N/A

APLS

YTD

-45.35%

1M

-0.29%

6M

-43.32%

1Y

-56.05%

3Y*

-25.72%

5Y*

-12.95%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Lantheus Holdings, Inc.

Apellis Pharmaceuticals, Inc.

Risk-Adjusted Performance

LNTH vs. APLS — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LNTH
The Risk-Adjusted Performance Rank of LNTH is 4444
Overall Rank
The Sharpe Ratio Rank of LNTH is 4646
Sharpe Ratio Rank
The Sortino Ratio Rank of LNTH is 4545
Sortino Ratio Rank
The Omega Ratio Rank of LNTH is 4747
Omega Ratio Rank
The Calmar Ratio Rank of LNTH is 3939
Calmar Ratio Rank
The Martin Ratio Rank of LNTH is 4343
Martin Ratio Rank

APLS
The Risk-Adjusted Performance Rank of APLS is 55
Overall Rank
The Sharpe Ratio Rank of APLS is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of APLS is 44
Sortino Ratio Rank
The Omega Ratio Rank of APLS is 55
Omega Ratio Rank
The Calmar Ratio Rank of APLS is 88
Calmar Ratio Rank
The Martin Ratio Rank of APLS is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

LNTH vs. APLS - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Lantheus Holdings, Inc. (LNTH) and Apellis Pharmaceuticals, Inc. (APLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current LNTH Sharpe Ratio is -0.10, which is higher than the APLS Sharpe Ratio of -1.05. The chart below compares the historical Sharpe Ratios of LNTH and APLS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

LNTH vs. APLS - Dividend Comparison

Neither LNTH nor APLS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

LNTH vs. APLS - Drawdown Comparison

The maximum LNTH drawdown since its inception was -78.62%, roughly equal to the maximum APLS drawdown of -82.47%. Use the drawdown chart below to compare losses from any high point for LNTH and APLS. For additional features, visit the drawdowns tool.


Loading data...

Volatility

LNTH vs. APLS - Volatility Comparison

Lantheus Holdings, Inc. (LNTH) has a higher volatility of 27.26% compared to Apellis Pharmaceuticals, Inc. (APLS) at 16.42%. This indicates that LNTH's price experiences larger fluctuations and is considered to be riskier than APLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

LNTH vs. APLS - Financials Comparison

This section allows you to compare key financial metrics between Lantheus Holdings, Inc. and Apellis Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M20212022202320242025
372.76M
166.80M
(LNTH) Total Revenue
(APLS) Total Revenue
Values in USD except per share items

LNTH vs. APLS - Profitability Comparison

The chart below illustrates the profitability comparison between Lantheus Holdings, Inc. and Apellis Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20212022202320242025
63.8%
79.4%
(LNTH) Gross Margin
(APLS) Gross Margin
LNTH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported a gross profit of 237.70M and revenue of 372.76M. Therefore, the gross margin over that period was 63.8%.

APLS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a gross profit of 132.44M and revenue of 166.80M. Therefore, the gross margin over that period was 79.4%.

LNTH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported an operating income of 102.07M and revenue of 372.76M, resulting in an operating margin of 27.4%.

APLS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported an operating income of -83.33M and revenue of 166.80M, resulting in an operating margin of -50.0%.

LNTH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Lantheus Holdings, Inc. reported a net income of 72.95M and revenue of 372.76M, resulting in a net margin of 19.6%.

APLS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Apellis Pharmaceuticals, Inc. reported a net income of -92.23M and revenue of 166.80M, resulting in a net margin of -55.3%.